摘要
目的研究拉米夫定与恩替卡韦对比治疗乙肝病毒所致慢加急性肝功能衰竭的效果。方法将乙肝病毒所致慢加急性肝功能衰竭297例分为2组,观察组行恩替卡韦治疗,对照组行拉米夫定治疗。结果 2组治疗前后ALB、TBIL、PTA、ALT差异有统计学意义(P<0.05),观察组总有效率(96.64%)高于对照组(79.73%),其治疗后4周、12周、48周转阴率(78.52%、87.25%、96.64%)高于对照组(48.65%、64.19%、79.73%),2组差异有统计学意义(P<0.05)。结论恩替卡韦治疗乙肝病毒所致慢加急性肝功能衰竭的效果优于拉米夫定,近期疗效明显,转阴率高。
Objective To compare the effects of lamivudine with that of entecavir in the treatment of Acute on chronic liver failure caused by HBV.Methods The hepatitis B virus-induced acute on chronic liver failure 297 cases were divided into two groups,the observation group line entecavir treatment,the control group underwent lamivudine.Results The two groups before and after treatment ALB,TBIL,PTA,ALT difference was statistically significant（P〈0.05）,the total efficiency of the observation group（96.64%） was higher（79.73%）,four weeks after the treatment,12 weeks,48 weeks negative rate（78.52%,87.25%,96.64%） was higher（48.65%,64.19%,79.73%）,two groups was statistically significant（P〈0.05）.Conclusion Entecavir treatment of hepatitis B virus-induced acute on chronic liver failure is better than lamivudine,obvious curative effect,negative rate.
出处
《中外医疗》
2015年第12期107-108,共2页
China & Foreign Medical Treatment
